Investor Relations Investor Center Stock Information Financial Information Corporate Governance Press Releases Events & Presentations Investor FAQ Contact Us
Press Releases Year None 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 Aug 24, 2026 Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share PDF Version Aug 21, 2026 Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer PDF Version Aug 12, 2026 Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update PDF Version Jul 16, 2026 Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders PDF Version May 13, 2026 Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update PDF Version Apr 15, 2026 Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B PDF Version Mar 23, 2026 Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update PDF Version Mar 03, 2026 Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna PDF Version Shareholder Tools Email Alerts Email Alerts RSS News Feeds RSS News Feeds Download Library Download Library
Press Releases Year None 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 Aug 24, 2026 Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share PDF Version Aug 21, 2026 Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer PDF Version Aug 12, 2026 Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update PDF Version Jul 16, 2026 Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders PDF Version May 13, 2026 Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update PDF Version Apr 15, 2026 Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B PDF Version Mar 23, 2026 Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update PDF Version Mar 03, 2026 Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna PDF Version
Aug 24, 2026 Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share PDF Version
Aug 21, 2026 Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer PDF Version
Aug 12, 2026 Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update PDF Version
Jul 16, 2026 Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders PDF Version
May 13, 2026 Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update PDF Version
Apr 15, 2026 Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B PDF Version
Mar 23, 2026 Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update PDF Version
Mar 03, 2026 Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna PDF Version
